Skip to content
10-K

Annual Report

Lazuriton Nano Biotechnology (U.S.A.) Inc.

0001640334-21-002291

← back to feed
Filed
Sep 22, 2021 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2020 · Dec 31, 2020 100M sh
Cash And Equivalents FY 2020 · Dec 31, 2020 $1.35K
Cash And Equivalents FY 2020 · Dec 31, 2019 $1.35K
Cash And Equivalents FY 2020 · Dec 31, 2018 $1.2K
Operating Cash Flow FY 2020 · Dec 31, 2019 $150
Current Liabilities FY 2020 · Dec 31, 2019 $269.88K
Total Liabilities FY 2020 · Dec 31, 2019 $269.88K
Current Assets FY 2020 · Dec 31, 2019 $1.35K
Total Assets FY 2020 · Dec 31, 2019 $1.35K
Sga Expense FY 2020 · Dec 31, 2019 $71.78K
Net Income FY 2020 · Dec 31, 2019 −$71.78K
Operating Income FY 2020 · Dec 31, 2019 −$71.78K
Revenue FY 2020 · Dec 31, 2019 $0
Stockholders Equity FY 2020 · Dec 31, 2018 −$196.76K